COMMUNIQUÉS West-GlobeNewswire
-
FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Completes Steps it Believes are Required to Regain Compliance
14/06/2024 - 23:30 -
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
15/06/2024 - 14:45 -
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
15/06/2024 - 16:00 -
The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
14/06/2024 - 12:00 -
Greenwich LifeSciences Announces $2.5 Million Private Placement
14/06/2024 - 12:00 -
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
14/06/2024 - 12:59 -
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
14/06/2024 - 13:00 -
Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
14/06/2024 - 13:00 -
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
14/06/2024 - 13:00 -
TScan Therapeutics Announces Updates to its Board of Directors
14/06/2024 - 13:00 -
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
14/06/2024 - 13:00 -
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
14/06/2024 - 13:01 -
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
14/06/2024 - 13:30 -
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
14/06/2024 - 13:30 -
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress
14/06/2024 - 13:30 -
Intellia Therapeutics Names Brian Goff to its Board of Directors
14/06/2024 - 13:30 -
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
14/06/2024 - 13:30 -
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
14/06/2024 - 13:50 -
Sharecare wins 22 Digital Health Awards in Spring 2024 competition
14/06/2024 - 14:00
Pages